The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: Suggested disease management guidelines

Archives of Internal Medicine

Volumn 156, Issue 5, 1996, Pages 477-484

  Fennerty, M Brian ^a   Castell, Donald ^b   Fendrick, A Mark ^c   Halpern, Michael ^d   Johnson, Daniel ^e   Kahrilas, Peter J ^f   Lieberman, David ^a   Richter, Joel E ^g   Sampliner, Richard E ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d BATTELLE MEMORIAL INSTITUTE   (United States)

^e Eastern Virginia School of Medicine   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR;

BARRETT ESOPHAGUS; COST BENEFIT ANALYSIS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEALTH CARE MANAGEMENT; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYPHYLAXIS; TREATMENT OUTCOME;

ALGORITHMS; DRUG THERAPY, COMBINATION; GASTROESOPHAGEAL REFLUX; HUMANS; MANAGED CARE PROGRAMS; PRACTICE GUIDELINES; QUALITY OF LIFE; RECURRENCE;

EID: 0029869458     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.5.477     Document Type: Review

References (59)

1. Hillman AL, Bloom BS, Fendrick AM Schwartz JJ. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med. 1992;152:1467-1472.
2. Patrick DL, Erickson E. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York, NY Oxford University Press Inc. 1993
3. Pope CE The quality of life following antireflux surgery. World J Surg. 1992;16:355-358.
4. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989;262 907-913.
5. Dimenas E Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol. 1993;28:18-21.
6. Dimenas E, Glise H, Hallerback B, et al Quality of life in patients with upper gastrointestinal symptoms: an improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681-687.
7. Brand DL, Eastwood IR, Martin D, Carter WB, Pope CE. Esophageal symptoms, manometry, and histology before and after antireflux surgery Gastroenterology. 1979,76.1393-1397.
8. Gallup Organization National Survey. Heartburn Across America. Princeton, NJ: Gallup Organization Inc; 1988.
9. Nebel OT, Fornes MF, Castell DO Symptomatic gastroesophageal reflux. incidence and precipitating factors. Am J Dig Dis. 1976;21.953-956.
10. Richter JE, Bradley LA, Castel DO. Esophageal chest pain: current controversies in pathogenesis, diagnosis and therapy. Ann Intern Med. 1989; 110:66-78.
11. Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the frequency and spectrum of causes and successful outcome of specific therapy. Am Rev Respir Dis. 1981,123.413-417.
12. Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991;90 576-583.
13. Sontag SJ, O'Connell S, Khandelwal S, et al Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology. 1990;99:613-620.
14. Dakkak M, Hoare RC, Maslin SC, Bennett GR. Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia. Gut 1993; 34:152-155.
15. Winters C, Spurling TJ, Chobanian SJ, et al Barrett's esophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-124.
16. Dent J, Dodds WJ, Friedman RH, et al Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest. 1980; 65:256-267
17. Wyman JB, Dent J, Heddle R Dodds WJ, Toouli J, Downton J. Control of belching by the lower esophageal sphincter. Gut. 1990,31:639-646.
18. Mittal RK, Rochester DF, McCallum RW. Electrical and mechanical activity in the human lower esophageal sphincter during diaphragmatic contraction J Clin Invest. 1988;81 1182-1189
19. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence' hiatus hernia, lower esophageal sphincter, or both? Ann Intern Med. 1992;117:977-982.
20. Johnson LF. 24-hour pH monitoring in the study of gastroesophageal reflux J Clin Gastroenterol. 1980;2:387-399.
21. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986;91 897-904.
22. Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia Gastroenterology. 1987,92:130-135.
23. Sloan S, Kahrilas PJ Impairment of esophageal emptying with hiatal hernia. Gastroenterology. 1991;100:596-605
24. Orr WC, Robinson MG, Johnson LF. Acid clearance during sleep in the pathogenesis of reflux esophagitis Dig Dis Sci. 1981;26:423-427.
25. Powell DW Barrier function of epithelia. Am J Physiol. 1981;241:G275-G288.
26. Cameron AJ. Zinsmeister AR, Ballard DJ, Carney JA Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99:918-922.
27. Sampliner RF, Hixson LJ, Fennerty MB, Garewal HS Regression of Barrett's esophagus by laser ablation in an antacid environment Dig Dis Sci. 1993;38:365-368
28. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci. 1990; 35.93-96.
29. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole in Barrett's esophagus. Am J Gastroenterol. 1994,89:1844-1848
30. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention and recurrence of benign oesophageal stricture. Gastroenterology. 1994;107:1312-1318.
31. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1994;89 989-991.
32. Hacker JF, Chobanian SJ, Johnson DA, Winters C, Cattau EL Patient acceptability of upper GI radiography versus endoscopy. South J Med. 1987;80:1091-1093.
33. Waring JP, Hunter JG, Oddsdottir M, Wo J, Katz E The preoperative evaluation of patients considered for laparoscopic antireflux surgery. Am J Gastroenterol. 1995;90.35-38.
34. Shindlebeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA. Three-year follow-up with patients with gastroesophageal reflux disease. Gut 1992;33:1016-1019.
35. McDougall NI, Johnston BT, Kee F, et al Three-year follow-up of reflux oesophagitis: do patients still require acid suppression therapy? Gut. 1994,35(suppl 4) A175. Abstract.
36. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole Gastroenterology. 1988; 95:903-912.
37. Johnson DA Medical therapy of gastroesophageal reflux disease Am J Med 1992;92(suppl 5A):88-97
38. Thomson ABR, Babiuk L, Kirdeikis P, et al. A dose ranging study of ranitidine in its effect on intragastric and intra-oesophageal acidity in subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1994;8:443-451.
39. Johnson NJ, Boyd EJS, Mills JG, Wood JR A key treatment of reflux oesophagitis a multi-centered trial to compare 150 mgs ranitidine b.d. with 300 mgs. ranitidine q.d.s. Aliment Pharmacol Ther. 1989;3:259-266
40. Bate CM, Keeling PW, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic endoscopic and histologic evaluations. Gut. 1990;31:968-972.
41. Bardhaan, KD, Morris P, Tompson M, et al. Omeprazole in the treatment of erosive oesophagitis refractory to high dose of cimetidine and ranitidine Gut. 1990,31:745-759.
42. 2 receptor antagonists. Aliment Pharmacol Ther. 1990;4:145-156.
43. Rianchai, Porro G, Pace F, Peracchia A Short-term treatment of refractory reflux oesophagitis with different doses of omeprazole or ranitidine J Clin Gastroenterol. 1992;15:192-198.
44. Havelund T, Laursen LS, Lauritsen K. Efficacy of omeprazole in lower grades of gastrooesophageal reflux disease. Scand J Gastroenterol. 1994;29(suppl 201):69-73
45. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid related disease. Drugs. 1994; 48:404-430.
46. Klinkenberg-Krol EC, Festen HP, Jansen JB, et al. Efficacy and safety of long-term treatment with omeprazole for refractory reflux esophagitis. Ann Intern Med 1994,121:161-167
47. Maton PN. Omeprazole. N Engl J Med. 1991; 324.965-975
48. Ramirez B, Richter JE. Review article: promotility drugs and the treatment of gastrooesophageal reflux disease Aliment Pharmacol Ther. 1993;7:5-20.
49. Geldof H, Hazelhoff B, Otten MH Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther. 1993; 7:409-415.
50. Robinson M, Deckator DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1993; 7 67-73
51. Mundo F, Felix R, Aguilar J, et al. Omeprazole vs ranitidine plus cisapride in the treatment of reflux oesophagitis: comparative endoscopic study Am J Gastroenterol. 1992,87:1254.
52. Swarbrick ET, Gough AL, Christian J, et al Prevention of recurrence of oesophageal stricture: a comparative study of lansoprazole and high-dose ranitidine. Gut. 1994,35(suppl 4) A175. Abstract.
53. Dent K, Yeomans ND, Mackinoon M, et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis: a double-blind trial of their efficacy and safety. Gut 1994;35:590-598
54. Hallerback B, Unge P, Carling L, et al. Omeprazole and ranitidine in long-term treatment of reflux oesophagitis. Gastroenterology 1994;107: 1305-1311.
55. Lundell L. Long-term treatment of gastrooesophageal reflux disease with omeprazole. Scand J Gastroenterol. 1994;29(suppl 201).74-78
56. 2 receptor antagonists in treating patients with peptic stricture and oesophagitis. Gastroenterology. 1994;106:907-915.
57. Lieberman DA. Medical therapy for chronic reflux esophagitis. Arch Intern Med. 1987;147: 1717-1720.
58. Just R, Katzka DA, Castell DO. Omeprazole failure in a patient with gastroesophageal reflux disease. Ann Intern Med. 1994;121 899.
59. Kasapidis P, Xynos E, Mantides A, et al. Differences in manometry in 24-hour ambulatory pH-metry between patients with and without endoscopic or histologic esophagitis and gastroesophageal reflux disease. Am J Gastroenterol 1993;88:1893-1899.